Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cellcor, Cytogen deal

CYTO signed a definitive agreement to acquire CLTX, a Newton, Mass., developer of autolymphocyte therapies (ALT) for cancer and infectious diseases.

CYTO (Princeton, N.J.) will issue

Read the full 260 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE